Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.

Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Review.

2.

Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.

Huang Y, Gilbert PB, Fu R, Janes H.

Biostatistics. 2017 Apr 1;18(2):230-243. doi: 10.1093/biostatistics/kxw043.

3.

HIV Vaccine Efficacy Trials: RV144 and Beyond.

Heger E, Schuetz A, Vasan S.

Adv Exp Med Biol. 2018;1075:3-30. doi: 10.1007/978-981-13-0484-2_1. Review.

PMID:
30030787
4.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Rolland M, Gilbert P.

AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/AID.2011.0240. Epub 2011 Sep 27.

5.

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND.

Contemp Clin Trials. 2006 Apr;27(2):147-60. Epub 2006 Jan 19.

PMID:
16426900
6.

Support for the RV144 HIV vaccine trial.

Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M.

Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. No abstract available.

PMID:
15247455
7.

Outstanding questions on HIV vaccine trial.

Jefferys R, Harrington M.

Science. 2004 Jul 9;305(5681):180; author reply 180. No abstract available.

PMID:
15247456
8.

Advances in HIV-1 Vaccine Development.

Gao Y, McKay PF, Mann JFS.

Viruses. 2018 Apr 1;10(4). pii: E167. doi: 10.3390/v10040167. Review.

9.

HIV-1 vaccines and adaptive trial designs.

Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS.

Sci Transl Med. 2011 Apr 20;3(79):79ps13. doi: 10.1126/scitranslmed.3001863.

10.

New clinical trial designs for HIV vaccine evaluation.

Moodie Z, Janes H, Huang Y.

Curr Opin HIV AIDS. 2013 Sep;8(5):437-42. doi: 10.1097/COH.0b013e328363d46a. Review.

11.

International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.

Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, Koff WC.

Asian Pac J Allergy Immunol. 1997 Jun;15(2):105-13.

PMID:
9346275
12.

HIV vaccine efficacy trials: towards the future of HIV prevention.

Kim D, Elizaga M, Duerr A.

Infect Dis Clin North Am. 2007 Mar;21(1):201-17, x.

PMID:
17502236
13.

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.

Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.

14.

Therapeutic vaccine trails in Thailand.

Churdboonchart V.

J HIV Ther. 2004 Sep;9(3):57-9. Review.

PMID:
15534562
15.

The design and evaluation of HIV-1 vaccines.

Saunders KO, Rudicell RS, Nabel GJ.

AIDS. 2012 Jun 19;26(10):1293-302. doi: 10.1097/QAD.0b013e32835474d2. Review.

PMID:
22706011
16.

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.

Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group.

Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.

17.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

18.

A shot at AIDS.

Koff WC.

Curr Opin Biotechnol. 2016 Dec;42:147-151. doi: 10.1016/j.copbio.2016.03.007. Epub 2016 May 3. Review.

PMID:
27153215
19.

Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JA.

Science. 2004 Jan 16;303(5656):316. No abstract available.

PMID:
14726576
20.

[HIV-1 vaccination--is there hope?].

Speck RF, Brander C, Kündig TM.

Ther Umsch. 2005 Oct;62(10):695-702. Review. German.

PMID:
16277037

Supplemental Content

Support Center